Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03632044 · ClinicalTrials.gov registry record · Phase 4

Evaluation of Trigeminal Nerve Blockade

A Phase 4 study of Cleft Palate and Birth Defect, sponsored by University of Florida.

Active
Registry status
Phase 4
Development phase
40
Enrollment target
1
Study location

NCT03632044 is a Phase 4 study of Cleft Palate and Birth Defect that is active but no longer recruiting, run by University of Florida. The registered enrollment target is 40 participants, below the 670-participant average among 9 other Cleft Palate trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03632044, a Phase 4 study of Cleft Palate and Birth Defect, is active but no longer recruiting, sponsored by University of Florida.

ACTIVE NOT RECRUITING
Registry status
Phase 4
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

Cleft palate repair requires high doses of opioids for pain control postop. An alternative approach is placement of nerve blocks in the pterygopalatine fossa bilaterally, blocking the maxillary nerve \& covering the entire midface. Application of bilateral suprazygomatic maxillary nerve blockade of the infraorbital nerve may provide effective analgesia for cleft lip repair, improving time to oral intake, pain control and time to hospital discharge.

Interventions

  • DRUG Ropivacaine
  • OTHER Sham Comparator

Study Locations (1)

Florida

  • UF Health - Gainesville

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2018-11-20
Est. Completion 2027-10-30
Phase Phase 4

Sponsor

University of Florida

1,106 total trials

What the Registry Record Tells You About NCT03632044

The ClinicalTrials.gov registry entry for NCT03632044 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 670-participant average among 9 other Cleft Palate trials with a reported enrollment target (94% lower). The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Cleft Palate appearing as the primary indexed condition, and to 2 interventions - of which Ropivacaine is the first listed.

NCT03632044 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT03632044 about?

NCT03632044 is a clinical study titled "Evaluation of Trigeminal Nerve Blockade". Cleft palate repair requires high doses of opioids for pain control postop. An alternative approach is placement of nerve blocks in the pterygopalatine fossa bilaterally, blocking the maxillary nerve \& covering the entire midface. Application of bilateral suprazygomatic maxillary nerve blockade of ...

What is the current status of trial NCT03632044?

This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2018-11-20. Estimated completion is 2027-10-30.

What conditions does trial NCT03632044 study?

This clinical trial studies the following conditions: Cleft Palate, Birth Defect, Mouth Abnormalities.

What interventions are being tested in trial NCT03632044?

The interventions under investigation include: Ropivacaine (DRUG), Sham Comparator (OTHER).

Who is sponsoring clinical trial NCT03632044?

This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03632044 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cleft Palate

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.